title: The integrated treatment of peritoneal carcinomatosis. A preliminary experience.
abstract: Some low-grade malignant tumors arising in the abdomen, lack of infiltrative attitude and "redistribute" on the peritoneum with no extraregional spreading. In this cases the complete tumor cytoreduction followed by intra- or postoperative regional chemotherapy has curative intent. Peritonectomy is the complete removal of all the parietal peritoneum and the visceral peritoneum involved by disease. After peritonectomy hyperthermic antiblastic perfusion is carried out throughout the abdomino-pelvic cavity for 60 minutes, at a temperature of 41.5 degrees C, with mitomycin C (3.3 mg/m2/Lt of perfusate) and cisplatin (25 mg/m2/Lt) (appendicular or colorectal primary), or cisplatin alone is (ovarian primary). Alternatively the immediate postoperative regional chemotherapy is performed with 5-fluorouracil (13.5 mg/Kg) and Lederfolin (125 mg/m2) (colic or appendicular tumor) or cisplatin (25 ng/m2) (ovarian tumor), each day for 5 days. Twenty patients affected by extensive peritoneal carcinomatosis (12 ovarian, 5 colonic, 1 appendicular, 1 mesothelial and 1 gastric primary) were submitted to peritonectomy with no residual macroscopic disease in all cases except three. Six patients were treated with intraoperative intra-abdominal hyperthermic antiblastic perfusion, while immediate postoperative intra-abdominal chemotherapy was given in 4 patients and systemic chemotherapy in other 5. Hospital mortality was 20%. At a mean follow-up of 11 months 14 patients are alive, 11 without disease and the median overall survival is 10.2 months. The curative potential of the combined therapeutic approach seems high in patients with peritoneal carcinomatosis from ovarian or colorectal primary not responding to systemic chemotherapy. Selection criteria of patients can strictly affect the surgical risk and the treatment has to be reserved for controlled clinical trials.
authors.affiliation: First Dept. of Surgical Oncology, Regina Elena Cancer Institute, Rome, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Cavaliere
authors.forename: F
authors.initials: F
authors.lastname: Di Filippo
authors.forename: M
authors.initials: M
authors.lastname: Cosimelli
authors.forename: L
authors.initials: L
authors.lastname: Aloe
authors.forename: E
authors.initials: E
authors.lastname: Arcuri
authors.forename: M
authors.initials: M
authors.lastname: Anzà
authors.forename: A
authors.initials: A
authors.lastname: Callopoli
authors.forename: L
authors.initials: L
authors.lastname: Di Lauro
authors.forename: E
authors.initials: E
authors.lastname: Morace
authors.forename: C
authors.initials: C
authors.lastname: Botti
authors.forename: S
authors.initials: S
authors.lastname: Natoli
authors.forename: M
authors.initials: M
authors.lastname: Tedesco
authors.forename: S
authors.initials: S
authors.lastname: Giunta
authors.forename: R
authors.initials: R
authors.lastname: Cavaliere
mesh_terms: D000008:Abdominal Neoplasms / Q000188:drug therapy / Q000601:surgery; D000293:Adolescent; D000328:Adult; D000368:Aged; D002277:Carcinoma / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery*; D017024:Chemotherapy, Adjuvant; D010478:Chemotherapy, Cancer, Regional Perfusion; D002945:Cisplatin / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000601:surgery; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D006979:Hyperthermia, Induced; D008297:Male; D008875:Middle Aged; D008937:Mitomycins / Q000627:therapeutic use; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000601:surgery; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary / Q000601:surgery*
chemical_list: D008937:Mitomycins; D002945:Cisplatin; D005472:Fluorouracil